The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2018 | Current approaches for treating relapsed MM
Currently there is a good variety of treatments available for patients with relapsed multiple myeloma (MM). Here, Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, of University College London Hospitals NHS Foundation Trust, London, UK, explores how best to make use of these different treatments. He discusses combining ixazomib with lenalidomide and dexamethasone to treat MM with few side effects, as well as the use of daratumumab monotherapy. Finally, Dr Popat discusses new immunotherapy treatment options, including the prospect of using anti-BCMA CAR T-cells. This video was recorded at the British Society for Haematology (BSH) 2018 Annual Meeting in Liverpool, UK.
